Tower Research Capital (TRC)’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.54M | Sell |
30,065
-7,517
| -20% | -$1.67M | 0.17% | 112 |
|
|
2025
Q4 | $8.59M | Buy |
37,582
+21,259
| +130% | +$4.84M | 0.21% | 81 |
|
|
2025
Q3 | $3.78M | Sell |
16,323
-37,511
| -70% | -$7.64M | 0.1% | 163 |
|
|
2025
Q2 | $9.99M | Sell |
53,834
-17,512
| -25% | -$3.25M | 0.27% | 61 |
|
|
2025
Q1 | $13.5M | Sell |
71,346
-21,581
| -23% | -$4.2M | 0.4% | 31 |
|
|
2024
Q4 | $16.5M | Buy |
92,927
+41,082
| +79% | +$7.55M | 0.33% | 46 |
|
|
2024
Q3 | $10.2M | Buy |
51,845
+1,661
| +3% | +$310K | 0.27% | 48 |
|
|
2024
Q2 | $8.61M | Buy |
50,184
+18,464
| +58% | +$3.06M | 0.15% | 105 |
|
|
2024
Q1 | $5.78M | Sell |
31,720
-213,794
| -87% | -$36.8M | 0.14% | 109 |
|
|
2023
Q4 | $38M | Buy |
245,514
+172,192
| +235% | +$25.1M | 0.47% | 28 |
|
|
2023
Q3 | $10.9M | Buy |
73,322
+40,548
| +124% | +$5.95M | 0.34% | 42 |
|
|
2023
Q2 | $4.42M | Sell |
32,774
-4,303
| -12% | -$631K | 0.15% | 97 |
|
|
2023
Q1 | $5.91M | Buy |
37,077
+3,969
| +12% | +$607K | 0.19% | 60 |
|
|
2022
Q4 | $5.35M | Sell |
33,108
-148,319
| -82% | -$22.7M | 0.22% | 57 |
|
|
2022
Q3 | $24.4M | Buy |
181,427
+78,204
| +76% | +$11.2M | 0.4% | 37 |
|
|
2022
Q2 | $15.8M | Sell |
103,223
-157,771
| -60% | -$24.1M | 0.35% | 45 |
|
|
2022
Q1 | $42.3M | Buy |
260,994
+165,369
| +173% | +$24M | 0.4% | 40 |
|
|
2021
Q4 | $12.9M | Buy |
95,625
+64,533
| +208% | +$7.62M | 0.22% | 73 |
|
|
2021
Q3 | $3.35M | Sell |
31,092
-61,097
| -66% | -$6.98M | 0.09% | 164 |
|
|
2021
Q2 | $10.4M | Sell |
92,189
-94,597
| -51% | -$10.7M | 0.27% | 54 |
|
|
2021
Q1 | $20.2M | Buy |
186,786
+121,468
| +186% | +$13M | 0.34% | 49 |
|
|
2020
Q4 | $7M | Buy |
65,318
+29,591
| +83% | +$2.84M | 0.21% | 42 |
|
|
2020
Q3 | $3.13M | Buy |
35,727
+4,789
| +15% | +$451K | 0.03% | 180 |
|
|
2020
Q2 | $3.04M | Buy |
30,938
+26,112
| +541% | +$2.3M | 0.12% | 126 |
|
|
2020
Q1 | $368K | Buy |
4,826
+4,795
| +15,468% | +$408K | 0.02% | 540 |
|
|
2019
Q4 | $3K | Sell |
31
-17,202
| -100% | -$1.43M | ﹤0.01% | 2864 |
|
|
2019
Q3 | $1.3M | Buy |
17,233
+15,695
| +1,020% | +$1.08M | 0.09% | 211 |
|
|
2019
Q2 | $112K | Sell |
1,538
-20,908
| -93% | -$1.64M | 0.01% | 1108 |
|
|
2019
Q1 | $1.81M | Sell |
22,446
-21,396
| -49% | -$1.75M | 0.11% | 143 |
|
|
2018
Q4 | $4.04M | Sell |
43,842
-1,097
| -2% | -$96.5K | 0.29% | 64 |
|
|
2018
Q3 | $4.25M | Sell |
44,939
-23,008
| -34% | -$2.18M | 0.31% | 48 |
|
|
2018
Q2 | $6.3M | Buy |
67,947
+66,747
| +5,562% | +$6.52M | 0.35% | 51 |
|
|
2018
Q1 | $114K | Sell |
1,200
-14,963
| -93% | -$1.64M | 0.01% | 1184 |
|
|
2017
Q4 | $1.56M | Buy |
16,163
+11,307
| +233% | +$1.07M | 0.2% | 102 |
|
|
2017
Q3 | $432K | Buy |
4,856
+2,227
| +85% | +$170K | 0.04% | 305 |
|
|
2017
Q2 | $190K | Buy |
2,629
+119
| +5% | +$8K | 0.02% | 352 |
|
|
2017
Q1 | $164K | Sell |
2,510
-31,212
| -93% | -$1.96M | 0.02% | 331 |
|
|
2016
Q4 | $2.11M | Buy |
33,722
+33,196
| +6,311% | +$2.03M | 0.23% | 100 |
|
|
2016
Q3 | $33K | Sell |
526
-5,014
| -91% | -$325K | ﹤0.01% | 1354 |
|
|
2016
Q2 | $343K | Buy |
5,540
+5,456
| +6,495% | +$332K | 0.03% | 391 |
|
|
2016
Q1 | $5K | Buy |
+84
| New | +$4.68K | ﹤0.01% | 2644 |
|
|
2015
Q3 | – | Sell |
-1,585
| Closed | -$106K | – | 3905 |
|
|
2015
Q2 | $106K | Buy |
1,585
+1,355
| +589% | +$88.5K | 0.01% | 750 |
|
|
2015
Q1 | $13K | Buy |
+230
| New | +$13.9K | ﹤0.01% | 2567 |
|
|
2014
Q4 | – | Sell |
-51,886
| Closed | -$3M | – | 3941 |
|
|
2014
Q3 | $3M | Buy |
51,886
+51,882
| +1,297,050% | +$2.88M | 0.34% | 56 |
|
|
2014
Q2 | $0 | Sell |
4
-1,070
| -100% | -$56.1K | ﹤0.01% | 3953 |
|
|
2014
Q1 | $55K | Buy |
1,074
+568
| +112% | +$28.7K | 0.01% | 1013 |
|
|
2013
Q4 | $27K | Sell |
506
-32,378
| -98% | -$1.59M | ﹤0.01% | 1980 |
|
|
2013
Q3 | $1.47M | Buy |
32,884
+30,399
| +1,223% | +$1.35M | 0.16% | 123 |
|
|
2013
Q2 | $103K | Buy |
+2,485
| New | +$109K | 0.01% | 491 |
|
Other funds holding ABBV
VCM
VPM
Tower Research Capital (TRC)'s ABBV Position: Q1 2026 in Review
Tower Research Capital (TRC) reduced its AbbVie (ABBV) stake by 20% in Q1 2026, selling an estimated $1.67M and leaving 30,065 shares worth $6.54M. The position accounts for 0.17% of the portfolio, ranked #112.
Tower Research Capital (TRC) first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $42.3M in Q1 2022. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Tower Research Capital (TRC) held 30,065 shares of AbbVie worth $6.54M as of Q1 2026.
- Tower Research Capital (TRC) sold 7,517 AbbVie shares in Q1 2026, an estimated $1.67M.
- AbbVie made up 0.17% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #112 holding.
- Tower Research Capital (TRC) first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
- Tower Research Capital (TRC)'s AbbVie position peaked at $42.3M in Q1 2022.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.